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Human cytomegalovirus evades antibody-mediated
immunity through endoplasmic reticulum-
associated degradation of the FcRn receptor
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Human cytomegalovirus (HCMV) can persistently infect humans, but how HCMV avoids
humoral immunity is not clear. The neonatal Fc receptor (FcRn) controls IgG transport from
the mother to the fetus and prolongs IgG half-life. Here we show that US11 inhibits the
assembly of FcRn with β2m and retains FcRn in the endoplasmic reticulum (ER), consequently
blocking FcRn trafficking to the endosome. Furthermore, US11 recruits the ubiquitin enzymes
Derlin-1, TMEM129 and UbE2J2 to engage FcRn, consequently initiating the dislocation of
FcRn from the ER to the cytosol and facilitating its degradation. Importantly, US11 inhibits IgG-
FcRn binding, resulting in a reduction of IgG transcytosis across intestinal or placental epi-
thelial cells and IgG degradation in endothelial cells. Hence, these results identify the
mechanism by which HCMV infection exploits an ER-associated degradation pathway
through US11 to disable FcRn functions. These results have implications for vaccine devel-
opment and immune surveillance.
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Human cytomegalovirus (HCMV) is a herpesvirus thatinfects humans. While most infections with HCMV areasymptomatic, the virus can cause infectious mono-
nucleosis. In either case the virus progresses to latency and
infected persons become lifelong infectious carriers. However,
HCMV infections pose a life-threatening risk in immunocom-
promised patients, such as transplant recipients and patients
with uncontrolled HIV infection. In addition, due to its ability to
infect the developing fetus in utero via placental transmission,
HCMV is the leading infectious cause of congenital abnormalities
worldwide1.
HCMV can successfully evade the immune system and estab-
lish lifelong latency and persistent virus shedding. Viral infections
are normally controlled through antibody-mediated and cell-
mediated immunity; the latter involves CD4+ and CD8+ T
lymphocytes and natural killer (NK) cells. Cellular immunity is
essential for limiting HCMV disease2, and individuals with
genetic defects affecting cellular immunity are highly susceptible
to HCMV3,4. HCMV expresses the US2, US3, US6, US10, US11
proteins that inhibit CD4+ or CD8+ T-cell activation through
distinct mechanisms5–14. The HCMV proteins UL16, UL18,
UL40, UL140, UL141, UL142, UL148A, US18, and US20 plus
microRNA-UL112 inhibit NK cell activation by moderating
MICA, ULBP, and MICB, HLA-E, CD112, CD155- ligands,
which normally engage the stimulatory NK cell receptors15–23. By
altering surface levels of T-cell and NK cell receptor ligands,
HCMV interferes broadly with cell-mediated immunity.
Humoral immunity is also important for suppressing HCMV
infection. Anti-virus antibodies neutralize virions and stimulate
immune cells expressing one or more FcγRs24. Several reports
noted the importance of antibodies for controlling infection25;
CMV immunoglobulin is licensed for prophylaxis in transplant
recipients26 and is under study to reduce congenital CMV dis-
ease27. However, latent HCMV can reactivate and is shed, even in
the presence of HCMV-specific IgG28. HCMV can circumvent
neutralizing antibodies (nAb) because the heavily glycosylated
glycoprotein N is poorly recognized29 or the IgG Fc is found in
the viral envelope where it increases the infection of FcγR-
expressing cells30. Interestingly, the HCMV genome also
encodes several decoy FcγRs, which may indirectly prevent
the Fcγ-mediated effector consequences of anti-HCMV IgG
antibodies31–33.
The neonatal Fc receptor (FcRn) is composed of a heavy chain
(HC) in non-covalent association with β2m34,35. This association
is required for FcRn/β2m exit from the endoplasmic reticulum
(ER)36. Although FcRn shares structural characteristics with
MHC class I, it does not present antigenic peptides to cognate
T cells due to its narrowed antigen-binding groove37. Instead,
FcRn binds IgG antibodies in a pH-dependent manner with FcRn
binding to the Fc-region of IgG at a pH below 6.5 and releasing
IgG at higher pHs38. The FcRn is normally transported to early
endosomes and has limited cell surface expression. Within these
acidic endosomes, FcRn binds endocytosed IgG39. Depending on
the cell type, FcRn either recycles IgG back to its original cell
surface, as is the case with endothelial cells, or transports IgG to
the opposite cell surface as is the case with certain polarized
epithelial cells in the intestine or placenta. The near neutral pH of
the extracellular environment triggers the release of IgG from
FcRn. Endocytosed IgG that does not bind FcRn moves to lyso-
somes where it is degraded39. FcRn therefore prolongs the half-
life of IgG. As an antibody transporter, FcRn helps to establish
passive immunity by carrying maternal IgG across the placental
syncytiotrophoblast monolayer, as well as across polarized epi-
thelium lining the respiratory, intestinal, and genital tracts40–42.
Also, FcRn is a target for delivering drugs, therapeutics, and
vaccines43–45. In all, FcRn plays a critical role in establishing early
neonatal immunity and is involved with immune responses to
both natural infection and vaccination.
Little is currently known about the interaction between HCMV
and FcRn. HCMV infects placental trophoblasts, epithelial cells,
endothelial cells, and hematopoietic stem cells46–50; Among the
hematopoietic cell lineage, FcRn expression is restricted to mye-
loid cells, including macrophages and dendritic cells39,43,51.
Maternal immunity is central to protection of the fetus because
infection can occur when neutralizing IgG is low48, although the
role of FcRn has remained somewhat elusive52. As FcRn is
important in passive immunity, its inactivation could lead to
superinfection of an unprotected developing fetus. Here, we have
identified that the HCMV glycoprotein US11 specifically captures
human FcRn, inhibits its antibody trafficking functions, and
causes its degradation in a process known as endoplasmic
reticulum-associated degradation (ERAD). This process may be
involved with dampening mucosal and maternal immunity and
reducing IgG half-life in blood and tissues. We therefore propose
a mechanism through which HCMV escapes antibody-mediated
immunity.
Results
HCMV glycoprotein US11 interacts with FcRn. Genes encoding
HCMV proteins, US2, US3, US6, US10, US11, UL16, and UL18
were cloned by PCR amplification of viral DNA. We then probed
for interactions between FcRn and each individual HCMV protein.
HeLaFcRn cells were transfected with plasmids encoding each of
the HA-tagged HCMV cDNAs. Owing to its affecting FcRn sta-
bility, we characterized US11 and FcRn interaction in this study.
HeLaFcRn or HeLa cells were transfected with plasmids
encoding HA-tagged US11 cDNA. Cell lysates were used for
immunoprecipitation with either anti-FLAG (for FcRn) (Fig. 1a)
or anti-HA (for US11) (Fig. 1b) mAb. The anti-FLAG Ab co-
immunoprecipitated US11 protein (Fig. 1a) and the anti-HA
Ab co-immunoprecipitated FcRn HC (Fig. 1b). We analyzed the
co-localization between FcRn and US11 using confocal micro-
scopy (Fig. 1c). FcRn appeared in a punctate pattern within
HeLaFcRn cells, while US11 was highly colocalized with FcRn in
HeLaFcRn+US11 cells (Fig. 1c). To identify the specificity, we co-
expressed FcRn with US2, and US11 with HFE that has an MHC
class I-like structure in HeLa cells. We failed to detect an
interaction between US11 and HEF (Fig. 1d, e), US11 and
endogenous transferrin receptor (TfR1) (Supplementary Fig. 1a),
or FcRn and US2 (Supplementary Fig. 1b, c) in a reciprocal
immunoprecipitation.
To further characterize the interaction between FcRn and
US11, we infected several types of cells, including primary human
umbilical vein endothelial cells (HUVEC), endothelial HMEC-1,
THP-1 cells, and intestinal epithelial Caco-2, with clinical strain
HCMV (MOI 5). The infection was verified by detecting HCMV
phosphoprotein 65 (PP65) (Supplementary Fig. 2). At day 2 post
infection (p.i.), we determined that anti-US11 Ab co-
immunoprecipitated with FcRn HC in infected HUVEC cells
(Fig. 1f). Similarly, anti-FcRn Ab was also found to co-
immunoprecipitate with US11 protein in infected HUVEC cells
(Fig. 1g). The US11 and FcRn interaction was also present in
either monocytic THP-1 (Supplementary Fig. 3a, b) or PMA-
differentiated macrophage-like THP-1 cells (Supplementary
Fig. 3c, d), HMEC-1 (Supplementary Fig. 3e, f), and Caco-2
(Supplementary Fig. 3g, h). These results indicate that that FcRn
and US11 interaction occurs in multiple cell types during HCMV
infection. Using GST-tagged US11 or cytoplasmic tail (CT) FcRn
proteins, we also found that the main site of contact between
US11 and FcRn is between their extracellular domains (Supple-
mentary Fig. 4a–c).
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US11 expression reduces FcRn traffic to the early endosome. In
most cell types, most FcRn resides in acidic endosomes where
FcRn binds pinocytosed or endocytosed IgG39. We hypothesized
that FcRn distribution in the endosome would be affected by the
interaction of US11 with FcRn HC. In HeLaFcRn+US11 cells, co-
localization of FcRn and the early endosomal marker EEA1 (early
endosomal Ag-1) was significantly decreased compared with
control HeLaFcRn cells (Fig. 2a, b). This suggests that US11
impairs FcRn endosomal trafficking. The reduction of co-
localization between FcRn and EEA1 is unlikely due to the
decreased expression of FcRn in HeLaFcRn+US11 cells because the
same HeLaFcRn cell line was used for transfecting the US11
expression plasmid and for control cells to monitor the level of
FcRn expression. Although the over-expression of FcRn does not
affect its intracellular trafficking pattern53,54, the over-expression
of US11 may cause extensive remodeling of intracellular
membranes. To investigate this possibility, we compared the
co-localization of transferrin receptor (TfR1, CD71) with EEA1
between HeLaFcRn and HeLaFcRn+US11 cells (Fig. 2c). We found
there was no significant difference in co-localization of TfR1 with
EEA1 between HeLaFcRn and HeLaFcRn+US11 cells (Fig. 2d),
suggesting that the potential remodeling of cellular membranes
by the over-expression of US11 may not affect endogenous pro-
tein trafficking. Altogether, these data confirm that the routing of
FcRn to endosomes in epithelial cells is significantly reduced by
US11.
The functional FcRn molecule consists of the HC bound to
β2m, we tested whether US11 interacts with FcRn HC or FcRn-
β2m. Lysates from HeLaFcRn+US11 were immunoprecipitated with
anti-HA (for US11) or anti-β2m Ab and blotted with anti-β2m
(BBM1) Ab to detect β2m (Fig. 2e) or anti-HA Ab to detect US11
(Fig. 2f). Immunoprecipitates were sequentially blotted with Abs
against US11, FcRn, or β2m. Anti-HA Ab failed to co-


















































































































































































1  21  2
10 μm 10 μm 10 μm 10 μm
10 μm10 μm10 μm10 μm
10 μm 10 μm 10 μm 10 μm
Fig. 1 FcRn interacts with HCMV US11. a, b The cell lysates from HeLaFcRn+US11 (lane 1), HeLaFcRn (lane 2), HeLaUS11 (lane 3), and HeLa control cells (lane
4) were immunoprecipitated by mAb anti-HA for US11 or anti-FLAG for FcRn. The immunoprecipitates were subjected to western blotting with anti-FLAG
or HA mAb as indicated. Cell lysate from each sample with equal amounts of total protein (input, 20 μg) were blotted with the indicated Abs. c Co-
localization of FcRn and US11 in HeLaFcRn+US11 cells. HeLaFcRn cells or HeLaUS11 cells were used as a control. Puncta that appear yellow in the merged
images (right panel) indicate co-localization of FcRn with US11 protein. The nuclei were stained with DAPI (blue). Scale bar: 10 μm. d, e Cell lysates from
HeLaHFE+US11 (lane 1), HeLaHFE (lane 2), HeLaUS11 (lane 3), and HeLa control cells (lane 4) were immunoprecipitated with mAb anti-HA for US11 or anti-
FLAG for HFE, respectively. The immunoprecipitates were subjected to western blotting with anti-FLAG or HA mAb as indicated. The cell lysates (input)
were blotted as control. f, g US11 interacts with FcRn in HCMV-infected human primary umbilical vein endothelial cells (HUVEC). HUVEC were infected
with HCMV at an MOI of 5. At day 2 p.i., the cell lysates from infected or mock-infected HUVEC were immunoprecipitated with anti-US11 Ab (f) or anti-
FcRn Ab (g). The immunoprecipitates were subjected to 12% SDS-PAGE electrophoresis under reducing conditions, then transferred to a nitrocellulose
membrane for western blotting with anti-FcRn or US11 Ab as indicated. The cell lysates (20 μg) were blotted as controls
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pull down US11 (Fig. 2f). However, an Ab against either HA or
β2m co-immunoprecipitated FcRn HC. These data strongly
suggest that HCMV US11 interacts with β2m-free FcRn HC.
FcRn has one N-linked glycosylation site55. To identify the
glycosylation status of FcRn in US11+ cells, we treated cell lysates
with either Endo H glycosidase, which cleaves high-mannose
oligosaccharides formed only in the ER, or with PNGase amidase,
which cleaves hybrid and complex oligosaccharides formed in
both the ER and golgi complex. FcRn HC from HeLaFcRn+US11
cells was much more sensitive to Endo H digestion than FcRn
from HeLaFcRn cells (Fig. 2g, top panel). As expected, FcRn from
both cell lines was sensitive to PNGase F digestion. We then
tested the Endo H sensitivity of FcRn in anti-US11 immunopre-
cipitates from HeLaFcRn+US11 cells. As shown in Fig. 2g (lower
panel), FcRn HC (lane 2) in a US11 immunoprecipitation from
HeLaFcRn+US11 cells demonstrated a mobility similar to FcRn HC
after PNGase F digestion (lane 3). The full sensitivity of FcRn HC
to Endo H digestion conforms to an ER-specific glycosylation
pattern of FcRn within the FcRn/US11 complex (Fig. 2h). Overall,
these findings strongly support our conclusion that the known
failure of newly synthesized FcRn to assemble with β2m and
traffic to the early endosome during HCMV infection is due to its
physical association with US11.
US11 is necessary for FcRn degradation during HCMV infec-
tion. To examine how US11 affects FcRn expression, we first
compared the expression levels of surface and intracellular FcRn
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found that US11 diminished both the surface and intracellular
expression level of FcRn (Fig. 3a). In contrast, US11 affected
neither the surface nor the intracellular expression level of HFE
under the same conditions (Fig. 3b), suggesting a specific
downregulation of FcRn by US11.
To specifically monitor the rate of FcRn HC degradation, we
performed a quantitative cycloheximide (CHX) chase assay.
HeLaFcRn+US11 (Fig. 3c) and HeLaFcRn (Fig. 3e) cells were treated
with CHX (100 μg/ml) and FcRn intensity detected in western
blot was measured by the Image Lab for the indicated times. In
HeLaFcRn+US11 cells, the US11 expression induced a significant
and time-dependent decrease in FcRn expression (Fig. 3c, d) in
comparison with that of HeLaFcRn cells (Fig. 3e). FcRn in US11+
cells also had a shorter half-life, compared to the long-term
stability of FcRn in control cells. Therefore, US11 promotes FcRn
protein degradation. In contrast, we did not detect a significant
change in the levels of β2m (Fig. 3f), suggesting that the effect of
US11 on FcRn levels was not due to either US11- or CHX-
induced cytotoxicity.
To identify whether this effect of US11 on endogenous FcRn is
seen during HCMV infection, we infected HUVEC or Caco-240.
Forty-eight hours post infection, we performed a quantitative
CHX-chase analysis. Compared to mock-infected controls (Fig. 3i
and Supplementary Fig. 5c), the expression levels of FcRn HC
were significantly decreased in HCMV-infected HUVEC cells
(Fig. 3g, h) or Caco-2 cells (Supplementary Fig. 5a, b). FcRn
mRNA levels did not change in Caco-2 cells (Supplementary
Fig. 5f–i), indicating that FcRn is not regulated by HCMV at the
transcriptional level. This FcRn downregulation during infection
was further supported by decreasing intracellular levels of FcRn in
HCMV-infected THP-1 and HMEC-1 cells using flow cytometry
(Supplementary Fig. 6a, b). To identify the role of US11 in this
process, we used two independent US11 small-interfering RNA
(siRNA) species to knock-down US11 in HCMV-infected cells.
FcRn degradation was significantly reduced in US11 siRNA-
treated HUVEC (Fig. 3h, k) or Caco-2 (Supplementary Fig. 5b, e),
although β2m levels were unaffected in HUVEC cells (Fig. 3j, k)
or Caco-2 cells (Supplementary Fig. 5d, e). We also noticed that
the FcRn level at 240 min post chase (Fig. 3k and Supplementary
Fig. 5e) was moderately restored by US11 siRNA in virus infected
cells in comparison with mock-infected cells (Fig. 3i and
Supplementary Fig. 5c). It is likely that this result was associated
with the incomplete blocking of US11 expression by US11 siRNA,
which was shown in a US11 blot (Fig. 3k and Supplementary
Fig. 5e, middle panels). In addition, we also found a mutant
HCMV ΔUS2-12 that lacks the US2-12 genes failed to induce a
significant and time-dependent decrease in FcRn expression in
HCMV ΔUS2-12-infected HEEFcRn cells in comparison with that
of mock or HCMV-infected cells (Supplementary Fig. 7). Taken
together, these results strongly suggest that US11 is required for
decreasing the intracellular concentration of FcRn during HCMV
infection.
US11 recruits Derlin-1 and TMEM-129 proteins to engage
FcRn. Derlin-1 can interact with US1156,57 and facilitates
movement of misfolded proteins through the ER membrane58.
We identified Derlin-1 as a potential partner of the FcRn-US11
complex. The US11–Derlin-1 interaction is dependent on a polar
glutamine residue (Q192) in the US11 transmembrane domain59.
To identify interactions between FcRn, US11, and Derlin-1, we
transfected HeLaFcRn cells with plasmids encoding Derlin-1 and
either a wild-type or mutant US11 Q192L. Using an anti-FLAG
Ab against FcRn, we co-immunoprecipitated US11 and Derlin-1
(Fig. 4a, lane 1), or mutant US11 without Derlin-1 (Fig. 4a, lane
2). Using an anti-Myc Ab against Derlin-1, we co-
immunoprecipitated both FcRn HC and US11 (Fig. 4b, lane 1),
but failed to pull down FcRn in the presence of mutant US11
Q192L (Fig. 4b, lane 2), verifying that Derlin-1 is incapable of
binding mutant US11 Q192L. Furthermore, anti-FLAG Ab
against FcRn did not co-immunoprecipitate Derlin-1 in the
absence of US11 (Fig. 4c, lane 1). Conversely, the FcRn levels
were maintained in HeLaFcRn+US11 Q192L cells during the CHX
treatment, suggesting that the observed FcRn decrease is medi-
ated through interactions between US11 and Derlin-1 (Fig. 4d, e).
Altogether, these data suggest that the Derlin-1 binding activity of
US11 is required for FcRn degradation.
Derlin-1 is known to interact with the E3 ligases. A thorough
screening of the candidate ligases in the presence of both US11
and Derlin-1 showed that the E3 ligase TMEM12960,61 was
recruited to the FcRn/US11/Derlin-1 complex (Fig. 4f, g). In the
absence of US11 expression, immunoprecipitation of FcRn failed
to pull down TMEM129 (Fig. 4f, lane 2). In addition, TMEM129
was capable of directly pulling down Derlin-1 in HeLaFcRn cells
without US11 (Fig. 4g, lane 2), suggesting that the binding of
TMEM129 to Derlin-1 is US11-independent. The recruitment of
TMEM129 to the FcRn/US11 complex is through Derlin-1, as the
wild-type US11 co-precipitated with TMEM129 while the Derlin-
binding mutant US11 Q192L failed to pull down TMEM129
(Supplementary Fig. 8a).
With this information in hand, we further decided to identify
the role of TMEM129 in the downregulation of FcRn in
HeLaFcRn+US11 cells. We found that depletion of TMEM129
using siRNA (Fig. 4h, bottom) reduced the loss of FcRn
expression in HeLaFcRn+US11 cells (Fig. 4h, i), suggesting that
TMEM129 is critical for US11-mediated degradation of FcRn. We
Fig. 2 US11 expression retains FcRn in the endoplasmic reticulum (ER). a, c FcRn or CD71 appearance in the endosome in HeLaFcRn+US11 and HeLaFcRn cells.
HeLaFcRn+US11 and HeLaFcRn cells were transfected with a plasmid expressing human CD71-GFP (green). Both cells were immunostained for FcRn (green)
and EEA1 (red). b, d Averages of the EEA1 and FcRn or CD71 co-localization in HeLaFcRn+US11 and HeLaFcRn cells. Pearson’s correlation coefficient was
measured in ten different optical regions (100 cells total) in each experiment. Error bars represented mean ± SEM of ten different optical regions. The
nuclei were stained with DAPI (blue); co-localization of two molecules appears in yellow. Scale bar: 10 μm. Similar images were seen from at least three
independent staining experiments. EEA1: early endosome antigen 1. ***P < 0.001, NS: no significance by Student’s t-test. e, f β2m or US11 does not co-
immunoprecipitate with US11 or β2m protein. Cell lysates from HeLaFcRn+US11 (lane 1), HeLaFcRn (lane 2), HeLaUS11 (lane 3), and HeLa cells (lane 4) were
immunoprecipitated by anti-HA mAb (e), anti-β2m Ab (f). All immunoprecipitates or cell lysates (20 μg) as internal controls were subject to western
blotting with corresponding Abs as indicated. g, h Sensitivity of US11-associated FcRn HC to Endo-H digestion. g Native FcRn in cell lysates (top panel) or
proteins immunoprecipitated by HA mAb (bottom panel) were digested by mock (lanes 1 and 4), Endo-H (lanes 2 and 5), or PNGase F (lanes 3 and 6) for
2 h at 37 °C, respectively. All immunoprecipitates or cell lysates (20 μg) were subject to western blotting with corresponding Abs as indicated. The ratio of
Endo H-resistant (Endo-HR) FcRn HC to Endo H-sensitive (Endo-HS) FcRn HC from HeLaFcRn+US11 and HeLaFcRn cells were compared by the ratio of the
band density of glycosylated FcRn to that of the deglycosylated FcRn (h). The band density of Endo-H-sensitive or resistant FcRn (g, top panel, lanes 2 and
5) was quantified by the software Image Lab 5.2. *P < 0.05 by Student’s t-test. Error bars represented mean ± SEM of three independent repeats. R:
Resistant; S: Sensitive
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therefore conclude that TMEM129 is responsible for US11-
mediated FcRn degradation.
FcRn cytoplasmic tail is necessary for degradation by US11. We
have shown that the extracellular domains of US11 and FcRn
interact with each other (Supplementary Fig. 4b, c). It is unknown
whether the cytoplasmic tail (CT) of FcRn plays a role in US11-
mediated degradation. To elucidate the involvement of the FcRn
CT, we generated a tailless FcRn (Fig. 5a), leaving five residues
allowing the proper insertion of the protein into the membrane62.
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Fig. 3 US11 protein mediates FcRn degradation. a, b Cell surface and intracellular expression patterns of FcRn and HFE in either fixed or permeabilized US11-
expressing cells were measured by flow cytometry. Cells were stained as described in Methods. The red or blue histograms represent staining of cells
with anti-FLAG (FcRn or HFE)-specific Ab with or without expression of US11, and the black histograms represent cells stained with isotype-matched IgG.
The staining was performed three times with similar results. The mean fluorescence intensity (MFI) is shown on the x-axis, and the relative cell number on
the y-axis. Results are expressed as histograms of fluorescence intensity (log scale). c–f HeLaFcRn cells were transfected with US11 plasmids for 24 h.
HeLaFcRn+US11 (c) and HeLaFcRn (e) cells were then treated with CHX (100 μg/ml) for the indicated time. The cells were lysed after CHX treatment and cell
lysates (20 μg) were subject to western blotting with corresponding Abs as indicated. The level of remaining FcRn (d) and β2m (f) at different time points
was quantified as the percentage of the β-tubulin level. g–k HUVEC cells were infected with clinic strain HCMV (MOI 5) (g) or mock-infected (i) for 48 h.
The infected cells were also transfected with 20 nM US11 siRNA oligomers (k). Forty-eight hours later, cells were then treated with CHX (100 μg/ml) for
the indicated time. The cells were lysed after CHX treatment and cell lysates (20 μg) were subject to western blotting with corresponding Abs as indicated.
The level of remaining endogenous FcRn (h) and β2m (j) in HUVEC cells at different time points was quantified as the percentage of the β-tubulin level. The
percentage of time point 0 (min) is assigned a value of 100% and the values from other time points are normalized to this value (d, f, h, j). Error bars
represented mean ± SEM of three independent repeats
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like full-length FcRn in assembling with β2m and pH-dependent
binding to IgG53. To examine this, HeLaUS11 cells were trans-
fected with either a WT FcRn or FcRn-tailless plasmid (Fig. 5b).
The fate of both proteins was further examined using a CHX-
chase experiment. In the absence of proteasome inhibitor, FcRn
HC was degraded by 60 min post chase (Fig. 5b, c). This was in
marked contrast with tailless FcRn, which persisted in the pre-
sence of US11 (Fig. 5b, c). To identify the critical region within
the FcRn CT that is responsible for its degradation, we con-
structed a series of C-terminal FcRn deletion mutants and
examined their susceptibility to US11-mediated degradation. We































































































































1 2 3 4








FcRn + US11   FcRn + US11Q192L  























































































































1 2 3  4
1 2 3 4
FcRn + US11


































1 2 3 4









Fig. 4 US11 recruits FcRn to Derlin-1 and TMEM129 protein complex. a–c US11 recruits FcRn to the Derlin-1 complex. US11Q192L represents a mutant US11
in which Q192 is replaced with leucine. Stable HeLaFcRn, HeLaFcRn+US11, HeLaFcRn+US11 Q192L, HeLaUS11, and HeLaUS11 Q192L cell lines were transfected with a
plasmid encoding myc-tagged Derlin-1. Forty-eight hours after transfection, the cell lysates (0.5 mg) were immunoprecipitated with mAb anti-FLAG for
FcRn (a, c) or anti-myc for Derlin-1 (b). Non-transfected HeLaFcRn or HeLa cells were used as a negative control. d, e FcRn in mutant US11Q192L transfected
cells resists degradation. HeLaFcRn+US11 and HeLaFcRn+US11* cells were treated with CHX (100 μg/ml) for the indicated time (d). Cells were lysed after CHX
treatment and cell lysates (20 μg) were subject to western blotting with corresponding Abs as indicated. The level of remaining FcRn (e) at different time
points was quantified as the percentage of the β-tubulin level. f, g US11 recruits FcRn to TMEM129 complex. HeLaFcRn+US11 (lane 1), HeLaFcRn (lane 2),
HeLaUS11 (lane 3), and HeLa cells were transfected with Derlin-1 plasmid. Forty-eight hours later, the cell lysates were immunoprecipitated by mAb anti-
FLAG for FcRn (f) or anti-TMEM129 Ab (g). h, i TMEM129 is involved in US11-mediated FcRn degradation. The HeLaFcRn+US11 cells were transfected with
20 nM TMEM129 siRNA oligomers (h, bottom). Forty-eight hours later, cells were then treated with CHX (100 μg/ml) for the indicated time. The cells
were lysed after CHX treatment and cell lysates (20 μg) were subjected to western blotting with Abs as indicated. The level of remaining FcRn (i) in
TMEM129 siRNA-treated cells (red) or mock-treated cells (black) at different time points was quantified as the percentage of the β-tubulin level. All
immunoprecipitates or cell lysates (20 μg) as controls were subject to western blotting with corresponding Abs as indicated (a, b, c, f, and g). The
percentage of time point 0 (min) is assigned a value of 100% and the values from other time points are normalized to this value (e, i). Error bars: mean ±
SEM of three independent repeats
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Fig. 5 The cytoplasmic tail of FcRn contributes to US11-mediated degradation. a Depiction of tailless FcRn (CT−/−) and FcRn HC deleting alanine residue
365 (365A−/−) in the cytoplasmic tail. Letter(s) in red represent(s) the deleted amino acid(s). b, c Tailless FcRn or FcRn 365A−/− resists degradation in
the presence of US11. HeLaUS11 (b, top), HeLaUS11+FcRn CT−/− (b, middle), or HeLaUS11+FcRn365−/− cells (b, bottom) were treated with CHX (100 μg/ml)
and chased for the indicated time in the absence of proteasome inhibitors. The cells were lysed after CHX treatment and cell lysates (20 μg) were subject
to western blotting with Abs as indicated. The level of wild-type FcRn (c, red), tailless FcRn (c, blue), and mutant FcRn 365A−/− (c, black) in HeLaUS11
cells at different time points was quantified as the percentage of the β-tubulin level. The percentage of time point 0 (min) is assigned a value of 100% and
the values from other time points are normalized to this value (c). Error bars represented mean ± SEM of three independent repeats. d The US11 interacts
with tailless FcRn protein. The cell lysates from HeLaFcRn+US11 (lane 1), HeLaUS11+FcRn CT−/− (lane 2), and HeLacontrol (lane 3) were immunoprecipitated by
anti-FLAG Ab for FcRn. The US11 molecules that coprecipitate in the complex are indicated. e The cytoplasmic tail of FcRn is required for tightly binding to
Derlin-1 in the presence of US11. HeLaFcRn+US11 (lane 1), HeLaUS11+FcRn CT−/− (lane 2), and HeLaUS11+FcRn 365A−/− (lane 3) cells were transfected with
Derlin-1 plasmid. Forty-eight hours later, cell lysates were immunoprecipitated with anti-FLAG Ab to detect FcRn. f The C-terminus of Derlin-1 is required
for tightly binding to FcRn in the presence of US11. The HeLaUS11+FcRn stable cells were transfected with a plasmid encoding Myc-tagged Derlin-1 (WT),
Derlin-1 lacking its N-terminus (NT−/−) or C-terminus (CT−/−), respectively. Forty-eight hours after transfection, the cell lysates (0.5 mg) were
immunoprecipitated with rabbit anti-FLAG Ab. All immunoprecipitates or cell lysates (20 μg) as internal controls were subject to western blotting with
corresponding Abs as indicated (d–f)
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its susceptibility to US11-induced degradation in a manner like
that observed after deleting the entire FcRn CT (Fig. 5b, c).
Indeed, the half-life of FcRn-365A−/− was comparable with that
of FcRn-tailless in HeLaUS11, while the alanine deletion also
rendered FcRn resistant to US11-induced degradation (Fig. 5b, c).
We therefore demonstrate that the FcRn CT is necessary for its
degradation.
To gain a deeper understanding of how the FcRn CT is
involved during US11-induced degradation of FcRn HC, we next
determined how FcRn CT interacts with US11 and Derlin-1.
Using co-precipitation (Fig. 5d), we found that our FcRn tailless
mutant maintained an interaction with US11. However, FcRn
tailless had a markedly reduced interaction with Derlin-1
(Fig. 5e; compare lanes 1 and 2). In addition, we found that
FcRn-365A−/− also had a similarly decreased interaction with
Derlin-1 (Fig. 5e; compare lanes 1 and 3). Finally, immunopre-
cipitation of tailless FcRn failed to precipitate TMEM129,
suggesting that the interaction between FcRn CT and Derlin-1
is also important for TMEM129 recruitment (Fig. 5e). When
HeLaUS11+FcRn cells were transfected with a plasmid encoding
Derlin-1, Derlin-1 lacking its N-terminus (NT−/−) or C-
terminus (CT−/−), and FcRn was immunoprecipitated, we
found that the C-terminus of the Derlin-1 was required for tight
binding to FcRn in the presence of US11 (Fig. 5f, lane 3). Taken
together, these results suggest that FcRn CT is required for US11-
induced degradation, perhaps via its interaction with Derlin-1.
US11/Derlin-1/TMEM129/Ube2J2 complex induces FcRn dis-
location, ubiquitination, and degradation. Ubiquitination of a
protein substrate is a critical step in protein degradation63. We
then investigated whether US11 regulates FcRn turnover through
a ubiquitination-dependent mechanism. We transfected
HeLaFcRn cells with either WT or a mutant US11Q192L. We
found that US11 specifically induced FcRn ubiquitination in the
presence of proteasome inhibitor, MG132 (Fig. 6a, b). However,
the mutant US11 Q192L failed to trigger FcRn ubiquitination
(Supplementary Fig. 8b), suggesting that the Derlin-1 is required
for FcRn ubiquitination. Furthermore, FcRn tailless (Fig. 6c, lane
2) and FcRn CT365A−/− (Fig. 6c, lane 3) exhibited significantly
less ubiquitination in comparison with WT FcRn (Fig. 6c, lane 1),
indicating that FcRn CT is necessary for US11-induced FcRn
ubiquitination.
We also detected FcRn proteins as both slow and fast migrating
bands (Fig. 6c, lane 1, middle). We found that FcRn from
HeLaFcRn+US11 cells migrated slowly during early CHX-chase
time points (Fig. 6d, lane 4) and faster (Fig. 6d, lanes 5–6) during
later time points in the presence of both US11 and MG132. We
reasoned this faster band might represent removal of the FcRn
glycan by cytosolic N-glycanase. To determine this, we subjected
HeLaFcRn+US11 or HeLaFcRn cells to a subcellular fractionation
and used the extracts from either the pellet (membrane) or
supernatant (cytosol) for blotting analysis of FcRn. Using Endo H
or PNGase F digestion, we found that the slower migrating form
of FcRn in the membrane fractions of HeLaFcRn corresponded to
Endo H-resistant protein (Fig. 6e, middle). However, FcRn HC
from HeLaFcRn+US11 cells was much more sensitive to Endo H
digestion (Fig. 6e, middle), and some FcRn was present in the
membrane fraction only and displayed normal maturation into a
slower migrating form. As shown in Fig. 6e (middle), the faster
migrating bands (lanes 3 and 4) from the membrane and cytosol
fractions of HeLaFcRn+US11 cells had a mobility similar to the
sensitive bands from Endo H digestion. As expected, FcRn from
either source was sensitive to PNGase F digestion (Fig. 6e,
bottom). We therefore conclude that the two forms of FcRn
represent a glycosylated version, which co-fractionates with the
ER membrane, and a cytosolic, non-glycosylated version of FcRn.
The origin of this non-glycosylated FcRn form could be due to
dislocation of FcRn from the ER; the cytosolic N-glycanase
removes the glycan from the FcRn.
The TMEM129 contains an atypical RING domain with
intrinsic E3 ubiquitin ligase activity60,61. To show that TMEM129
is necessary for FcRn ubiquitination, we knocked down
TMEM129 expression (Fig. 7a, middle, lane 2). We then
immunoprecipitated FcRn and found the robust FcRn ubiquiti-
nation induced by US11 (Fig. 7a, top, lane 1) was abrogated in
TMEM129 siRNA-treated cells (Fig. 7a, top, lane 2). The atypical
RING-C2 domain of TMEM129 creates a binding platform for E2
conjugating enzymes. Previous studies60,61 implied that Ube2J1
or Ube2J2 is a potential player in the TMEM129-mediated FcRn
ubiquitination, we observed that knock-down of Ube2J2, but not
Ube2J1, nearly abolished US11-induced FcRn ubiquitination
(Fig. 7b, top, lane 1) and rescued FcRn from degradation in
HeLaFcRn+US11 cells (Fig. 7c, d). We conclude that the TMEM129
recruits Ube2J2 for US11-induced FcRn ubiquitination, leading to
its eventual ER dislocation and proteasome degradation.
US11 reduces IgG transcytosis in epithelial cell monolayers. To
examine whether HCMV infection or US11 alone affects FcRn-
mediated IgG transcytosis across polarized epithelial cells, we first
tested whether the association of FcRn with US11 affects FcRn
binding to IgG. FcRn is known to bind IgG at pH below 6.5 and
to release IgG at neutral pH38. Lysates from HeLa cells expressing
FcRn and/or US11 were incubated with IgG-Sepharose at either
pH 6.0 or pH 7.4. Eluates and cell lysates were subjected to
analysis by western blot. As expected, FcRn from HeLaFcRn cells
bound IgG at pH 6.0 (Fig. 8a, lane 2), but not at pH 7.4 (Fig. 8b,
lane 2). Similarly, β2m from the IgG binding eluates was detected
at pH 6.0 (Fig. 8a, lane 2), but not at pH 7.4 (Fig. 8b, lane 2). We
did not detect US11 proteins in the FcRn binding eluates of IgG
beads at pH 6.0 (Fig. 8a, lane 1). Furthermore, FcRn and β2m
levels (Fig. 8a, lane 1) eluted from IgG beads were remarkably
decreased in HeLaFcRn+US11 cells when compared to in HeLaFcRn
cells alone (Fig. 8a, lane 2). These data strongly suggest that the
association of US11 with FcRn HC interferes with FcRn binding
to IgG.
FcRn transports IgG across the polarized epithelial cells40,42.
HCMV can infect Caco-2 cells at the basolateral membrane64. We
explored the possibility that HCMV-infected Caco-2 epithelial
cells have altered IgG transcytosis. We added human IgG Abs to
the apical surface of a Caco-2 cell monolayer at 37 °C and then
measured IgG transport into the opposite basolateral chamber
using cells infected with HCMV in the basolateral surface. After 2
h, IgG transport was significantly (P < 0.001) decreased or
blocked in HCMV-infected Caco-2 cells (Fig. 8e, lane 2, Fig. 8f)
when compared to mock-infected cell monolayers. We also
showed that IgG transport was significantly decreased (P < 0.001)
or blocked in HCMV-infected placental epithelial BeWo cells
(Fig. 8g, lane 3; Fig. 8h) as compared with mock-infected BeWo
cell monolayers (lane 1).
Infecting Caco-2 monolayers with HCMV for 48 h may result
in a leakage. To further show whether US11 expression alone
reduces IgG transcytosis, we stably expressed US11 in Caco-2
cells (Supplementary Fig. 9a). Then, IgG (0.5 mg/ml) was added
apically into the Caco-2US11 cell monolayer and further incubated
for 2 h to allow for transcytosis. We then collected the basolateral
medium and measured IgG. As seen in Caco-2US11 cells, IgG
transport was significantly decreased (P < 0.001) (Fig. 8i, lane 2;
Fig. 8j) as compared with mock-transfected cells (Fig. 8i, lane 4;
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Fig. 8j). IgG was not transported at 4 °C in HCMV-infected Caco-
2 (Fig. 8e, lane 4) or BeWo cells (Fig. 8g, lane 4), and US11-
expressing Caco-2 cells (Fig. 8i, lane 1), suggesting that
transepithelial flux of IgG Abs by passive diffusion across
intercellular junctions or monolayer leaks did not contribute to
the amount of detected IgG. Hence, we conclude that US11
inhibits IgG transport across polarized epithelial cells.
US11 expression facilitates IgG degradation. FcRn plays a cri-
tical role in IgG homeostasis39,65–67. If US11 acts by preventing
FcRn binding to IgG and trafficking to the endosome, it should
consequently accelerate IgG degradation by promoting the traf-
ficking of pinocytosed IgG to the lysosomes for degradation. To
test this hypothesis, HCMV-infected endothelial HMEC-1 cells
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Fig. 6 US11 induces FcRn dislocation and ubiquitylation. a–d FcRn is ubiquitinated in the presence of US11 and MG132. HeLaFcRn (a), HeLaHFE (b), HeLaFcRn
CT−/− (c, lane 2), and HeLaFcRn 365A−/− (c, lane 3) cells were transfected with or without US11 plasmids for 48 h, and cells were treated with proteasome
inhibitor MG132 (50 μM) for 2 h, as indicated. HeLaFcRn or HeLaFcRn+US11 cells (d) were treated with CHX (100 μg/ml) and chased for the indicated time in
the presence of MG132. Cell lysates (0.5 mg) were immunoprecipitated with mAb anti-FLAG for FcRn (a, c, d) or HFE (b). All immunoprecipitates or
cell lysates (20 μg) as internal controls were subject to western blotting with corresponding Abs as indicated. e Fractionation of FcRn HC. HeLaFcRn,
HeLaUS11+FcRn cells were incubated in the presence or absence of 50 μM MG132 for 4 h. Cells were then homogenized and the homogenates were
fractionated by centrifugation (see Methods). FcRn in the membrane pellet (M, lanes 1, 3, 5, 7) and supernatant (S, lanes 2, 4, 6, 8) fraction was digested
by mock (top), Endo-H (middle), PNGase F (bottom) enzymes for 2 h at 37 °C, respectively. R: resistant; S: sensitive. After treatment all fractions were
subject to western blotting with corresponding Abs as indicated
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after a 48 h incubation, the level of IgG that was recycled back to
the supernatant was significantly reduced (P < 0.01) in HCMV-
infected HMEC-1 cells in comparison with that in mock-infected
cells (Fig. 9a, b). To further elucidate this process, we stained
HCMV-infected HMEC-1 cells with anti-EEA1 mAb to visualize
IgG trafficking to the endosome. We detected IgG in the endo-
some of mock-infected HMEC-1 cells, but much less in the
HCMV-infected cells (Fig. 9c, d). To further investigate the fate of
IgG, lysosome-associated membrane glycoprotein-1 (LAMP-1), a
lysosomal marker, was used to track IgG trafficking to lysosomal
sites. Lysosomal transport of IgG was negligible in mock-infected
HMEC-1 cells during the incubation period (Fig. 9e). However,
co-localization (Fig. 9e, yellow) of LAMP-1 and IgG was more
prominent in HCMV-infected HMEC-1 cells, suggesting that
HCMV infection promotes lysosomal trafficking of IgG. Pear-
son’s correlation coefficient analysis indicated significant co-
localization of IgG with endosomal (Fig. 9d) but much less
lysosomal (Fig. 9f) markers in mock-infected HMEC-1 cells. IgG
trafficking patterns in HCMV-infected HMEC-1 cells were ver-
ified in IgG-treated HeLaFcRn+US11 cells (Supplementary Fig. 10).
The IgG degradation accelerated by US11 was further verified in
IgG recycling experiments, as HCMV infection or US11 expres-
sion significantly reduced the IgG recycling in either HMEC-1
cells or HeLaFcRn cells (Supplementary Fig. 11). Taken together,
these data strongly suggest that US11 prevents FcRn endosomal
trafficking, ultimately resulting in the delivery of IgG to lyso-
somes for degradation.
Discussion
Misfolded proteins are translocated across the ER-membrane,
destined for cytosolic proteasome degradation in a process known
as ERAD68. Many pathogens including HCMV, exploit the ERAD
system to nullify important components of the host immune
system69,70. The success of HCMV to infect a large proportion of
the world’s population is due at least in part to its ability to evade
the cellular immune system, and we have found that the virus also
inhibits antibody responses. We initially hypothesized that
HCMV infection impeded FcRn trafficking from the ER, leading
to its absence in the acidic endosomal compartment and ren-
dering it unable to bind IgG. In this study, we demonstrate that
HCMV infection causes FcRn degradation through an ERAD
mechanism and thus, removes a critical feature of host immunity.
We first determined that the HCMV protein US11 colocalizes
with FcRn in transfected or HCMV-infected cells. This observa-
tion led us to measure a specific interaction between US11 and
FcRn in human epithelial, endothelial, and macrophage cells. Our
results in THP-1 cells were especially encouraging, because cells
in the monocyte lineage are known to be a reservoir for latent
HCMV infection. We subsequently identified early immature
glycosylation patterns on the US11–FcRn complex, suggesting
that the complex is retained in the ER and supporting the
observation that US11 is an ER resident protein71. We then
observed that the presence of US11 correlates with an absence of
FcRn in early endosomes. We also determined that US11 inter-
acts with nascent FcRn HC but not with FcRn-β2m, suggesting
that US11 captures newly synthesized FcRn HC before it binds
β2m. The exact molecular interactions between US11 and FcRn
have yet to be fully characterized, but it seems that the US11
luminal domain targets the extracellular domain of FcRn, and we
will investigate the contribution of a critical residue to this
interaction. We found the evidence that the HCMV genome
encodes other proteins that interact with FcRn HC. These addi-
tional HCMV proteins may affect FcRn function and make the
functional studies more complexed in using US11 mutant virus.
Interestingly, we observed no degradation of FcRn tailless,
even in the presence of US11 binding, suggesting that US11 is
not sufficient for FcRn degradation and the FcRn cytosolic tail is
necessary for trafficking into the degradative ERAD pathway. We
discovered that US11 interacts with Derlin-1 that was capable of
causing FcRn degradation. We also observed that deletion of the
Derlin-1 cytosolic tail also prevented it from tightly binding to
FcRn HC. We postulate that the interaction of the FcRn and
Derlin-1 cytoplasmic tails may allow both molecules to engage

















HeLa (FcRn + US11)


























































































Fig. 7 TMEM129 and Ube2J2 are required for US11-induced FcRn ubiquitination, a, b TMEM129 and Ube2J2 is required for US11-induced FcRn
ubiquitination. HeLaFcRn+US11 cells were transfected with 20 nM TMEM129, Ube2J1, or Ube2J2 siRNA oligomers for 48 h or empty vector. Cells were
subsequently treated with 50 μMMG132 for 4 h and then lysed. All immunoprecipitates or cell lysates (20 μg) as internal controls were subject to western
blotting with corresponding Abs as indicated. c, d HeLaUS11+FcRn cells were transfected with 20 nM Ube2J1 (c, top) and Ube2J2 (c, bottom) siRNA
oligomers for 48 h. Cells were then treated with CHX (100 μg/ml) and chased for the indicated time. The cells were lysed after CHX treatment and cell
lysates (20 μg) were subject to western blotting with Abs as indicated. The level of remaining FcRn (d) in Ube2j1 siRNA-treated cells (black) or Ube2j2
siRNA-treated cells (red) was quantified as the percentage of the β-tubulin level at different time points. The percentage of time point 0 (min) is assigned a
value of 100% and the values from other time points are normalized to this value. Error bars represented mean ± SEM of three independent repeats
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Fig. 8 HCMV and US11 reduce FcRn-mediated IgG transcytosis in epithelial monolayers. a–d The presence of US11 reduces FcRn binding to IgG. HeLa
transfectants were lysed in pH 6.0 (a) or pH 7.4 (b) condition. Approximately 0.5 mg of soluble proteins were incubated with human IgG-Sepharose at
4 °C. Eluted proteins were subjected to western blotting analysis with corresponding Abs as indicated. Cell lysates were blotted as control. The amount of
eluted FcRn (c) or β2m protein from HeLaFcRn and HeLaFcRn+US11 cells was compared by the ratio of the band density of eluted protein to that of input
protein. The density of protein bands was quantified by the Image Lab 5.2 software. e–h Caco-2 cells (2 × 104/well) or BeWo cells (105/well) were grown
in 0.4 μm transwell for 8 to 10 days (Caco-2) or for 4 days (BeWo) to allow differentiation. When the transepithelial resistance r reached above 600
(Caco-2) or 400 (BeWo) ohms/cm2, cells were infected at the basolateral surface with HCMV (MOI 5) for 1 h. After washing, cells were incubated for
48 h. Infected or mock-infected cells were loaded at the apical surface with IgG (lanes 1–4) (0.5 mg/ml for Caco-2 or 0.25 mg/ml for BeWo) at 37 °C or
4 °C, respectively. Medium was collected from the basolateral compartment 2 h later and subjected to western blot (e, g) or ELISA (f, h) analysis. i, j Caco-
2 cells transfected with either pEF6 or pEF6-US11 plasmid were grown on transwell inserts. The cells were incubated for 1 h at 37 °C or 4 °C, then IgG
(0.5 mg/ml) was added to the apical surface and further incubated for 2 h to allow transcytosis. Medium from the basolateral compartment was collected
and IgG content was measured by western blot (i) or ELISA (j). *P < 0.05, **P < 0.01, and ***P < 0.001 by Student’s t-test. Error bars represented mean ±
SEM of three independent repeats
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ER dislocation machinery. We observed that FcRn, following its
capture by Derlin-1, is quickly dislocated, ubiquitinated and
released from the ER into the cytosol. Although Derlin-1 inter-
acts with a range of E3 ligases, its durable interaction with
TMEM129 made TMEM129 a strong candidate for the final
ubiquitination of FcRn. Structural analysis of TMEM129 iden-
tified it as a possible member of the RING family of E3
ligases60,61. We demonstrated that the knockdown of TMEM129
and its cognate E2 UbE2J2 abolishes FcRn ubiquitination and
prevents its degradation, even in the presence of US11. We
suggest that the major role of US11 is to facilitate FcRn binding
to Derlin-1, leading to TMEM129-mediated ubiquitination of
FcRn and its subsequent proteasomal degradation in the cytosol.
Thus, US11 harnesses a Derlin-1/TMEM129-dependent pathway
that is responsible for FcRn degradation. HCMV downregulated
FcRn expression in human foreskin fibroblast (HFF), which was
detected by mass spectrometry23. However, we failed to detect
FcRn expression by western blot analysis in either uninfected or
HCMV-infected HFF (Supplementary Fig. 12). This discrepancy
may be caused by the protein detection method or the low level
of FcRn expression in the HFF cells. More experiments are
needed to verify this result23.
We characterized the effects of US11 on FcRn-mediated IgG
transport and protection. As HCMV infection cycles through
periods of latency and reactivation, the long-lasting humoral
immune responses are generated through the production of IgG.
FcRn normally supports passive immunity in the neonate by
facilitating transfer of maternal IgG across the placenta. Post
delivery, FcRn continues to support an effective immune response
against infection by transporting IgG across polarized epithelium
lining mucosal surfaces40–42. FcRn therefore contributes to a
lifelong IgG-mediated immunity. For HCMV to evade immunity
and be shed despite a potent immune response, we suggest that it
must have developed a mechanism to inhibit FcRn. We found
that expression of US11 in cells reduced the ability of FcRn to
transport IgG across epithelial surfaces and resulted in reduced
half-life of the IgG. This observation could help explain the
association of HCMV with severe congenital infection72. We
propose that US11 may help HCMV avoid contact with IgG by
accelerating the catabolism of FcRn. This property of HCMV
would be especially important after virus reactivation in order to
maintain long-term infection and shedding in its host.
FcRn is normally glycosylated. These glycation moieties may
inhibit entry into the proteasome. We postulate that N-glycanase
likely removes these glycans following FcRn dislocation from the
ER. During our studies, we detected a deglycosylated form of
FcRn only in the cytosol (Fig. 6e). As the deglycosylated FcRn
intermediates are not observed in the absence of proteasomal
inhibitors, this suggests that the dislocation from the ER and
proteasomal degradation may be tightly coupled. This assump-
tion is supported by evidence that the C-terminal region of
Derlin-1 interacts with the cytosolic proteasomal protein AAA
ATPase p9773,74. Therefore, we suspect that p97 may interact
with Derlin-1-bound FcRn HC to provide the activation energy
necessary for FcRn extraction from the ER membrane into the
cytosol for proteasomal degradation. Our results imply that the
cytosolic region of FcRn is involved in ERAD substrate binding
and this interaction is critical for the Derlin-1-mediated dis-
location of FcRn to the cytosol during US11-induced FcRn
degradation.
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Fig. 9 HCMV infection increases IgG catabolism in human endothelial cells. a, b HEMC-1 cells (5 × 105/2ml) were grown in complete medium with 5% FBS
with ultra-low IgG. After cells were infected with 5 MOI of HCMV or mock-infected for 48 h, they were incubated with 50 μg/ml human IgG for 48 h at
37 °C. After washing, the cells were incubated at 37 °C. During the incubation, 50 μl of supernatant was sampled at 0, 12, 24, 36, and 48 h and the IgG
concentration in each sample was measured by ELISA (a). At 48 h, the IgG concentration in the medium from the HCMV-infected and mock-infected cells
was analyzed by t-test (b). **P < 0.01 by Student’s t-test. Error bars represented mean ± SEM of three independent repeats. c–f To visualize human IgG
trafficking inside infected HEMC-1 (5 × 104) cells, cells were infected with 5 MOI of HCMV for 48 h and incubated with 250 μg/ml human IgG for 1 h at
37 °C. After washing, cells were incubated in complete medium without IgG for an additional 1 h, then fixed and stained for co-localization of human IgG
with the early endosomal marker EEA1 (c) or lysosomal marker LAMP-1 (e). Scale bar: 10 μm. For Pearson’s correlation coefficiency measurement, ten
microscopic fields, each of which contained at least ten cells, were measured for correlation coefficiency rate (d, f). ***P < 0.001 by Student’s t-test. Error
bars represented mean ± SEM of three independent repeats
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US11 has previously been shown to degrade MHC class I
molecules through a Derlin-1/TMEM129-mediated ERAD sys-
tem, thereby hindering the recognition of infected cells by CD8+
cytotoxic T cells11,75. We have verified this finding in our study
(Supplementary Figs. 13 and 14). However, our discovery of
US11-mediated FcRn degradation is unexpected because FcRn
has limited homology with MHC-I. Previous studies reported the
HCMV protein US276 can also induce rapid degradation of newly
synthesized MHC-I. In contrast, HCMV US2 fails to induce FcRn
degradation. We suspect that HCMV is likely to possess multiple
immune-modulating proteins to degrade MHC-I molecules due
to their highly polymorphic nature but FcRn is relatively non-
polymorphic. Most surprisingly, we have found that this US11-
mediated ERAD degradation mechanism evades both cellular and
humoral immunity, thus providing HCMV an efficient option to
evade the human immune responses in a broad sense.
Several questions remain for future studies. First, the precise
sites of ubiquitination in US11-induced FcRn degradation remain
undefined. Human FcRn contains a single lysine residue in its
cytoplasmic tail55—whether this lysine residue is critical for FcRn
ubiquitination merits further investigation. Ubiquitination is
known to occur at nonlysine residues, including serine, threonine,
and cysteine77,78. Both serine and threonine residues appear in
the FcRn CT55, leading to the possibility of multiple ubiquitin
acceptor sites. In addition, TMEM129 may be able to ubiquitinate
a combination of lysine and nonlysine residues. US11 is observed
to degrade MHC-I molecules that do not contain lysine resi-
dues79, further supporting our notion that TMEM129-dependent
ubiquitination of FcRn HC may occur on a combination of lysine
and nonlysine residues. Second, we propose that US11 inhibits
intracellular trafficking of FcRn, leading to decreased IgG trans-
cytosis and increased IgG catabolism. These mechanisms cannot
be currently tested in vivo as HCMV is highly species-specific and
no animal model is available. Cytomegalovirus strains infect mice
and guinea pigs and it will be interesting to know whether these
strains also cause FcRn degradation. Third, FcRn has an impor-
tant role in the development of autoimmune disease80 because it
prolongs the half-life of autoreactive IgG. Thus, HCMV US11
might serve as a treatment for patients with autoimmune disease
by blocking FcRn function and facilitating the destruction of
autoreactive IgG.
In conclusion, we define a mechanism by which US11 sup-
presses humoral immunity through the inhibition of FcRn. We
therefore introduce a mechanism for the role of US11 as a
humoral immune suppressor. We propose a model that details
how HCMV US11 dislocates FcRn to the cytosol for subsequent
proteasomal degradation (Fig. 10). Our characterization of
HCMV US11-induced FcRn ubiquitination as a target by the
ERAD system therefore not only uncovers a function for the
ERAD pathway, but may better help in understanding HCMV
pathogenesis, treating viral diseases, and designing effective vac-
cines. Owing to the global prevalence of HCMV infection and the
important roles for FcRn in IgG transport and catabolism, this
study may impact work in multiple fields, including infectious
disease, rheumatology, and oncology.
Methods
Cell lines, enzymes, and viruses. Human intestinal epithelial Caco-2, human
placental trophoblast BeWo, human lung fibroblast MRC-5, cervical HeLa cell lines
were obtained from the American Type Culture Collection (ATCC, Manassas, VA)
and grown in complete DMEM. The human endothelial cell line HMEC-1, a
dermal-derived microvasculature cell line, was provided by the Centers for Disease
Control (Atlanta, GA). Human monocytic THP-1 cells (ATCC) and HMEC-1 cells
were grown in RPMI 1640 (Invitrogen, Carlsbad, CA) complete medium. Complete
media were supplemented with 10 mM HEPES, 10% FCS (Sigma-Aldrich, St. Louis,
MO), 1% L-glutamine, nonessential amino acids, and 1% penicillin-streptomycin.
To differentiate THP-1 cells into macrophages, cells were treated with 50 ng/ml
phorbol-12-myristate-13-acetate (PMA) for 48 h. Primary human umbilical vein
endothelial cells (HUVEC, ATCC PCS-100-013™) were purchased from ATCC and
grown in vascular cell basal medium (PCS-100-030™) supplemented with endo-
thelial cell growth kit-BBE (PCS-100-040™). Cells were grown in 5% CO2 at 37 °C.
The HCMV AD169 strain was purchased from ATCC. An HCMV clinical
strain, designated for CMV Bethesda BAL, was isolated from bronchoalveolar
lavage fluid in a patient who signed consent on an Institution Review Board
approved protocol (01-I-0161) at the National Institute of Allergy and Infectious
Diseases, National of Institutes of Health, Bethesda, MD. The virus was passaged
<5 times in MRC-5 cells before use in these experiments. Ten to fourteen day post
infection, cell-free virus was harvested by sonicating cell pellets, and the cellular
debris was removed by centrifugation at 6000 relative centrifugal force (rcf) for
20 min. Virus was concentrated by centrifugation at 20,000 rcf for 2 h through a
20% sucrose cushion. Virus titer was determined by quantifying TCID50 in MRC-5
(ATCC) cells using the Reed-Muench method. HCMVΔUS1-US1281 was a kind
gift from Dr. Fenyong Liu, University of California, Berkeley and Dr. Hua Zhu,
New Jersey Medical School, Rutgers University.
Antibodies and fluorescent dyes. The following antibodies were used for
detection of endogenous and overexpressed proteins by western blot analysis:
rabbit anti-Flag epitope (DYKDDDDK) (Sigma-Aldrich, cat# F7425; 1:5000), rat
anti-FLAG epitope (Biolegend, Cat# 637301; 1:5000), rat anti-HA epitope
(YPYDVPDYA) (Roche, cat# 11867423001; 1:5000), mouse anti-Myc epitope
(EQKLISEEDL) (Cell Signaling, Cat# 2276S; 1:5000), rabbit anti-Myc epitope (Cell
Signaling, Cat# 2278T; 1:2500), mouse anti-human FcRn (Santa Cruz Bio-
technology, Cat# Sc-271745; 1:500), rabbit anti-human FcRn (affinity purified,
1:500), mouse anti-US11 (Affinity-purified, 1:500), mouse anti-human β2m
(hybridoma BBM1; 1:500), rabbit anti-human β2m (Abcam, Cat# ab75853; 1:1000),
rabbit anti-human β-tubulin (Sigma-Aldrich, Cat# T2200-200UL; 1:2500), mouse
anti-HCMV PP65 (Abcam, Cat# ab6503; 1:2500), mouse anti-ubiquitin (Santa
Cruz Biotechnology, Cat# Sc-8017; 1:250), rabbit anti-human TMEM129 (Sigma-
Aldrich, Cat# SAB1302253; 1:500), mouse anti-human MHC class I (Enzo Life
Sciences, Cat# ALX-805-711-C100; 1:500), rabbit anti-human CD71 (TfR1) (Santa
Cruz Biotechnology, Cat# sc-9099; 1:500), mouse anti-human Ube2j1 (Santa Cruz
Biotechnology, Cat# sc-3777002; 1:500), rabbit anti-human Ube2j2 (Novus biolo-
gical, Cat# NBP1-59760 1:500). For detection by western blot, primary antibody
incubation was followed by incubation with appropriate secondary HRP-
conjugated goat anti-mouse/rabbit/rat/human (Southern Biotech, Cat# 1010-05/
4030-05/3030-05/2081-05, respectively) in a 1:5000 dilution. The following anti-
bodies against human antigens were used for immunoprecipitation in a 1:100
dilution: rabbit anti-FLAG epitope (Sigma-Aldrich, cat# F7425), rat anti-FLAG
epitope (Biolegend, Cat# 637301), mouse anti-HA epitope (hybridoma 12CA5,
affinity purified), mouse anti-Myc epitope (Cell Signaling, Cat# 2276S), rabbit anti-
human FcRn (affinity purified), mouse anti-human β2m (hybridoma BBM1), rabbit
anti-human TMEM129 (Sigma-Aldrich, Cat# SAB1302253). The following anti-
bodies were used for Flow cytometry: rat anti-FLAG epitope (Biolegend, Cat#
637301; 1:500), mouse anti-human FcRn (Santa Cruz Biotechnology, Cat# Sc-
271745; 1:500). For detection by confocal microscopy, primary antibody incubation
1 h on ice was followed by incubation with appropriate secondary goat anti-mouse
Alexa 488 (Life Technologies, Cat# A11001), goat anti-rat Alexa 488 (Life Tech-
nologies, Cat# A11006) in a 1:1000 dilution. The following antibodies were used for
confocal microscopy: rabbit anti-Flag epitope (Sigma-Aldrich, Cat# F7425; 1:500),
rat anti-HA epitope (Roche, Cat# 11867423001; 1:500), mouse anti-human EEA1
(BD Biosciences, Cat# 610457; 1:250), mouse anti-human LAMP-1 (BD Bios-
ciences, Cat# 611042; 1:250), rabbit anti-pp65 (biorbyt, Cat# orb10511; 1:250),
mouse anti-US11 (Affinity-purified, 1:200). For detection by confocal microscopy,
primary antibody incubation 1 h at room temperature was followed by incubation
with appropriate secondary goat anti-mouse Alexa 488/555 (Life Technologies,
Cat# A11001/A21424, respectively), goat anti-rabbit Alexa 555 (Life Technologies,
Cat# A21430), goat anti-rabbit Alexa 488 (Abcam, Cat# ab150077), goat anti-rat
Alexa 488 (Life Technologies, Cat# A11006), goat anti-human Alexa 555 (Life
Technologies, Cat# A21433) in a 1:1000 dilution. Goat anti-Human IgG Fc coating
antibody (Bethyl, Cat# A80-104P; 1:100) and goat anti-Human IgG Fc HRP-
conjugated antibody (Bethyl, Cat# A80-104P; 1:10000) were used for ELISA.
Viral infection of human cells. HeLa, THP-1, HMEC-1, BeWo, primary HUVEC,
and Caco-2 cell monolayers were infected with the HCMV clinical strain through
the addition of virus at a high MOI of 5 or 10. Prior to infection, cells were washed
once with Dulbecco’s phosphate-buffered saline (PBS). After the addition of virus,
infection proceeded for 2 h at 37 °C in an atmosphere of 5% CO2. After washing
three times with PBS, infected cells were cultured with fresh complete medium at
37 °C in an atmosphere of 5% CO2.
Construction of expression vectors and mutagenesis of US11. All primers used
for cloning or mutagenizing the genes in this study are summarized in Supple-
mentary Table 1. The construction of human β2m and FcRn expression plasmids,
pcDNAβ2m, and pcDNA-FLAGFcRn was previously described51. HLA-A2 cDNA
was amplified from HeLa total RNA by RT-PCR and was cloned into pcDNA-Flag
via Hind III and Xba I restriction site cloning. Homeostatic iron regulator (HFE)
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encoding the human hemochromatosis protein was amplified from pCMV-Sport-
HFE and cloned into pcDNA-Flag using Hind III and Xba I restriction site cloning.
An FcRn mutant without the cytoplasmic tail, FcRn CT−/−, or FcRn mutant
deleted for amino acid 365 in its C-terminus, FcRn 365A−/−, were amplified from
pcDNA-FLAGFcRn and subsequently cloned into pcDNA-Flag using Not I and
Xba I double digestions. To construct pSectag2-Derlin-1, Derlin-1 was amplified
from HeLa cDNA and its C-terminus was fused to a Myc epitope. The DNA
fragment was digested with Xba I and Xho I (underlined) and ligated into the
plasmid pSectag2, which was pre-digested with Nhe I (isocaudomer of Xba I) and
Xho I enzymes. A Derlin-1 mutant deleted for amino acids 1–66 in its N-terminus
(NT−/−) or deleted for amino acids 526–756 in its C-terminus (CT−/−) was
amplified from pSectag2-Derlin-1 and subsequently cloned into pSecTag Hygro A
plasmid using Xba I and Xho I double digestions. The pTFR1-GFP plasmid was a
gift from Dr. Gary Banker (Oregon Health and Science University, Portland, OR).
The purified HCMV AD169 DNA was only used as a template for synthesis of
HCMV genes, US11 or US2. In brief, the pEF6-US11 and pEF6-US2 constructs
were constructed by fusing an HA epitope to the N-terminus of either HCMV
US11 or the C-terminus US2 gene by the PCR primer pairs listed in Supplementary
Table 1. The N-terminal HA tag was inserted between the US11 signal peptide and
the US11 ORF. All DNA fragments were digested with BamH I and Xba I
(underlined) and ligated into the plasmid pEF6 to generate the plasmid pEF6-US11
or pEF6-US2. A US11 mutant was generated by mutation of a polar amino acid,
glutamine (Q) 192, within the US11 transmembrane domain to a hydrophobic
leucine (L) residue using a site-directed mutagenesis kit (Takara, Mountain View,
CA). The US11 DNA in the pEF6 expression vector was used as a template. The
oligonucleotide was used for the change of a glutamine (Q) 192 to a leucine (L)
residue, base substitutions are underlined. The resultant plasmids were designed for
pcDNAUS11Q192L. To construct a pGex4T1-US11, a PCR primer pair was used to
amplify a truncated 438 bp DNA fragment encoding the extracellular domain of
US11 gene. In the above cloning, the primer introduced a BamH I or Not I site
(underlined) to facilitate subcloning of the DNA fragment into the pGEX4T-1
(Amersham Pharmacia Biotech, Piscataway, NJ) expression vector. All constructs
were sequenced to verify the fidelity of amplification, cloning, and mutations. All
oligonucleotides used in this study are summarized (Supplementary Table 1).
Production of FcRn-specific and US11-specific antibody. Production of affinity-
purified FcRn-specific Abs was previously described53. Production of affinity-
purified glutathione S-transferase (GST) fusion proteins was done as previously
described53. In brief, recombinant GST-US11 proteins were produced in BL21 cells
(Invitrogen) following treatment with 0.2 mM IPTG (isopropyl-β-D-thiogalacto-
pyranoside) for 16 h. To produce anti-US11 antibodies, we immunized a mouse
with the purified GST-US11 fusion protein and Freund’s adjuvant. Anti-US11
antibodies were then affinity purified from the immunized mouse sera. The animal
experiment was approved by the University of Maryland Institutional Animal Care
and Use Committee.
Semiquantitative RT-PCR analysis. Semiquantitative RT-PCR was performed
according to the manufacturer’s instructions. In brief, Caco-2 cells (5 × 105) were
infected with HCMV (MOI 5) or mock-infected for 48 h, and then cells were
treated with CHX (100 μg/ml) from 30 to 240 min. Total RNA was isolated using
TRIzol (Invitrogen). First-strand cDNAs were obtained from total RNA (100 ng)
using a SuperScript™ III Reverse Transcriptase kit (ThermoScientific). Then the
cDNAs were used as the template for PCR amplification by human FcRn (5′-
GTACCTGAGCTACAATAGCCTG-3′, 5′-CACGGAAAAGCCAGGGCTGCTG-


























Fig. 10 Proposed model for US11 interaction with FcRn. In uninfected cells (right), FcRn traffics to the endosome and reaches the cell surface through the
secretory pathway and recycles between the plasma membrane and endosomes via endocytosis. In HCMV-infected cells or in cells expressing US11 (left),
a portion of the β2m-free FcRn HC molecules is associated with US11 in the ER. US11-bound FcRn is rapidly ubiquitinated by TMEM129 E3 ligase and
subsequently dislocated to the cytosol for proteasomal degradation. TMEM129 is recruited to US11 via Derlin-1. The portion of FcRn engaged by US11 is
targeted for proteasome degradation by ER ‘dislocation’’. The Figure was created by Dr. Xiaoping Zhu with assistance of the PowerPoint Drawing Diagrams
(http://www.motifolio.com)
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AGTTGTCATGGATGACCTTGGCC-3′) specific primers. Twenty-nine or 34
cycles of PCR amplification were performed in a 20-μl volume. Each cycle con-
sisted of denaturation at 94 °C for 30 s, annealing at 58 °C for 30 s, and extension at
72 °C for 30 s. An additional 10 min was applied for the final extension. PCR
products were resolved on 1.5% agarose gels and visualized by staining with
ethidium bromide. Integrated density values for the FcRn bands were normalized
to the GAPDH values to yield a semiquantitative assessment by densitometric
intensity analyses.
Transfection and protein expression. The stable cell line, HeLaFcRn, has been
described previously51. HeLa, HeLaFcRn, and Caco-2 cells were transfected with
either empty vector or the recombinant plasmid along with PolyJet transfection
reagent (SignaGen Laboratories, Rockville, MD). Single transfectants were selected
with G418 (1 mg/ml). Double transfectants were selected with G418 plus either
Blasticidin (5 μg/ml) or Hygromycin B (200 μg/ml). Positive clones were tested for
protein expression with western blot using anti-FLAG, anti-HA, and anti-Myc
antibodies. Successful transfectants were maintained in complete DMEM medium
containing G418 (400 μg/ml) ± Blasticidin (3 μg/ml). For transient transfections,
cells were transfected with 2 μg of plasmids. The level of protein expression was
examined 48 h post transfection by western blot. All transfected cells used in this
study are summarized in Supplementary Table 2.
Silencing of gene expression by siRNA. Pre-designed siRNA products were
synthesized from Genewiz (South Plainfield, NJ), including HCMV US11, human
TREM129, and Ube2j1 or Ube2j2 (Supplementary Table 3). Transfection of siRNA
oligonucleotides corresponding to US11, TREM129, or Ube2j genes was carried out
using Lipofectamine 2000 transfection agent (Invitrogen) at a final concentration of
20 nM mixed siRNA oligomers per well. Mock control was transfected without
adding the mixed siRNA oligomers. The US11 and TMEM129 genes were targeted
with two non-overlapping siRNAs to enhance effectiveness. For US11 knockdown
in primary HUVEC cells by siRNA, cells were transfected with 20 nM siRNA
oligomers per well using Nucleofection kit V (Lonza) 24 h before HCMV infection.
Knockdown efficiency was confirmed by western blot.
IgG binding assay. A human IgG binding assay was performed as previously
described51. Cells were lysed in PBS (pH 6.0 or 7.4) with 0.5% CHAPS (Sigma-
Aldrich) and protease inhibitor cocktail (Calbiochem) mixture on ice for 1–2 h.
The soluble proteins (0.5–1 mg) were incubated with human IgG-Sepharose
(Rockland Immunochemicals, Pottstown, PA) at 4 °C overnight. Unbound proteins
were washed off with PBS (pH 6.0 or 7.4) containing 0.5% CHAPS. Adsorbed
proteins were boiled with Laemmli Sample buffer at 95 °C for 5 min. The soluble
fractions were subjected to western blot analysis as described below.
Immunoprecipitation, gel electrophoresis, western blotting. Cell lines, trans-
fectants, or HCMV- or mock-infected cells (5 × 106) were lysed in PBS with 0.5%
CHAPS and protease inhibitor cocktail III (Roche, Branchburg, NJ). The cell
lysates were centrifuged at 6000 rpm at 4 °C to remove cell debris. Protein con-
centrations were determined by the Bradford method (Bio-Rad Laboratories).
Immunoprecipitations were performed54. In brief, the cell lysates (400 μl) were
incubated with 100 μl of a protein G agarose slurry plus 5 μg of primary Abs
specific for each protein at room temperature for 2 h. The protein G beads were
washed by 0.5% CHAPS buffer five times.
The cell lysates or the protein G beads were boiled with 2x Laemmli sample
buffer at 95 °C and resolved on a 12% sodium dodecyl sulfate polyacrylamide gel
electrophoresis (SDS-PAGE) gel under reducing conditions. Proteins were
transferred onto a nitrocellulose membrane (Schleicher & Schuell, Keene, NH) by
semi-dry transfer (Bio-Rad Laboratories, Hercules, CA). All blocking, incubation,
and washing were performed in 5% non-fat milk and 0.05% Tween 20 in PBS. The
membranes were blocked, probed separately with a specific primary Ab, washed,
and then probed with an HRP-conjugated secondary Ab for 2 h. Proteins were
visualized using immobilon western chemiluminescent HRP substrate (Millipore,
Billerica, MA). Chemiluminescence signal acquisition and densitometry analysis
were conducted using the Image Lab, version 5.2 in a Chemi-Doc XRS imaging
system (Bio-Rad Laboratories, Hercules, CA).
Analysis of N-linked glycosylation. N-linked glycosylation was analyzed54. In
brief, native FcRn in cell lysates or the proteins immunoprecipitated by HA murine
antibodies were digested with endo-β-N-acetylglucosaminidase H (Endo H; New
England Biolabs) in digestion buffer (100 mM sodium acetate, pH 5, 150 mM NaCl,
1% Triton X-100, 0.2% SDS, 0.5 mM PMSF) or with peptide: N-glycosidase F
(PNGase F; New England Biolabs) in 50 mM sodium phosphate, pH 7.5, with 1%
NP-40. A mock digestion without enzymes was performed as a control. All
digestions were performed for 2 h at 37 °C. Proteins were analyzed on a 12% SDS-
PAGE gel under reducing conditions and immunoblotted as previously described.
Cell fractionation. Cell fractionation was done as the previously described82. After
HeLaFcRn and HeLaFcRn+us11 cells were incubated with or without MG132 (50 μM)
at 37 °C for 4 h, cells were then pelleted and lysed by three freeze–thaw cycles.
Membrane fractions were pelleted from supernatants by ultracentrifugation at
100,000 × g (Beckman XL80, 28,700 rpm) for 2 h. Soluble (cytosolic) fractions were
collected and diluted in 1% Triton X-100. Pellet (membrane) fractions were washed
by PBS and resuspend in 1% Triton X-100 for further analysis.
Confocal immunofluorescence. Immunofluorescence was performed as pre-
viously described53. Briefly, cells were cultured on coverslips for 24 h at 37 °C.
Subsequent procedures were done at room temperature. The cells were rinsed in
PBS, fixed in cold 4% paraformaldehyde (Sigma-Aldrich) in PBS for 20 min, and
quenched with glycine for 10 min. After two washes with PBS, the coverslips were
permeabilized in solution (PBS containing 0.2% Triton X-100) for 5 min and then
blocked with blocking buffer containing 3% normal goat serum (NGS) for 30 min.
Antibodies diluted in blocking buffer were added onto the coverslips and incubated
for 1 h. Cells were then incubated with Alexa Fluor 488 or 555-conjugated goat
secondary antibodies in blocking buffer. Cell nuclei were stained with DAPI (4′, 6-
Diamidino-2-Phenylindole, Dihydrochloride) for 15 min. After each step, cells
were washed three times with 0.1% Tween 20 in PBS. Coverslips were mounted on
slides using the ProLong antifade kit (Molecular Probes) and examined using a
Zeiss LSM 510 confocal fluorescence microscope. Images were processed using
LSM Image Examiner software (Zeiss, Thornwood, NY). Quantitative co-
localization measurements were performed using Zeiss LSM 510 Examiner Soft-
ware. Pearson’s correlation coefficient was calculated for describing the co-
localization correlation of the intensity distributions between two channels, as
previously described83. In each quantitative experiment with the transfected HeLa
or infected HMEC-1 cells, 100 representative cells were analyzed. A value of P <
0.05 was considered significant.
Quantitative cycloheximide chase assay. Cells were treated with cycloheximide
(CHX) (100 μg/ml) (Calbiochem, San Diego, CA) for different time periods, lysed,
and protein levels were measured by Bradford assay. Each cell lysate (20 μg) was
analyzed by western blotting with corresponding antibodies. The levels of
remaining FcRn, HLA-A2, and β2m at different time points were calculated as the
percentage of β-tubulin (an internal control). The percentage of time point 0 (min)
was assigned a value of 100% and the values from other time points were nor-
malized to this value. The expression levels of proteins were quantified by the band
density (relative band volume) measured by software Image Lab 5.2. The degra-
dation experiments were repeated in triplicate.
Flow cytometry. Surface and intracellular expressions of FcRn were examined in
either fixed or permeabilized HeLa transfected, THP-1 cells, or HMEC-1 cells by
flow cytometry. Cells were washed with PBS, and if necessary, detached by 10%
EDTA. For cell surface staining, after blocking by 2% FBS, cells were incubated
with rat anti-FLAG Ab for 1 h on ice to minimize internalization. For intracellular
staining, cells, were first treated with cycloheximide (100 μg/ml) or left untreated as
a control for 4 h. Subsequently, they were incubated with Fixing/Permealizing
Buffer (BD CytoFix/CytoPer Kit) for 20 min. THP-1 cells were also treated with
30 μg/ml human Fc block (BD) for 10 min at room temperature. After washing
and blocking with 2% FBS, cells were incubated with anti-FLAG Ab or anti-FcRn
Ab for 1 h on ice. For all staining, cells were incubated with isotype-matched
control rat Abs to determine the background fluorescence. After washing with
PBS, the cells were incubated with Alexa Fluor 488-conjugated secondary Abs for 1
h on ice. Cells were fixed with 2% paraformaldehyde overnight and analyzed
using a FACSAria (Becton Dickinson, Franklin Lakes, NJ) and FlowJo software
(Tree Star).
Detection of protein ubiquitination in cultured cells. Cultured cells were
transfected with plasmids expressing US11 along with a FLAG-tagged version of
FcRn, HFE, and HLA-A2. Forty-eight hours later, cells were treated with 50 μM
MG132 (Calbiochem) for 2 h and subsequently lysed in PBS with 0.5% CHAPS and
protease inhibitor cocktail. The proteins (500–1000 μg) were incubated with anti-
FLAG murine Ab and protein G beads overnight at 4 °C. After the immunopre-
cipitates were washed three times with PBS containing 0.05% Tween 20 (PBST),
they were heated with Laemmli sample buffer at 95 °C and the eluted products were
further analyzed by SDS-PAGE and western blot analysis to detect ubiquitin and
the targeted proteins with respective antibodies.
Enzyme-linked immunosorbent assay. Human IgG was quantified using an
enzyme-linked immunosorbent assay (ELISA) kit (Bethyl Laboratories, Mon-
tgomery, TX). ELISA plates (Nalge Nunc, Rochester, NY) were coated with goat
anti-human IgG-Fc Ab (10 μg/ml) overnight at 4 °C. Plates were washed three
times with PBST and then blocked with 2% FBS in PBS for 1 h at room tem-
perature. Plates were washed with PBST three times and incubated with either an
IgG standard or the transcytosis samples diluted in 2% FBS for 2 h at 25 °C. Plates
were washed for five times with PBST and incubated with HRP-conjugated goat
anti-human IgG-Fc Ab (0.1 µg/ml) for 1 h. After plates were washed with PBST
seven times, tetramethylbenzidine and hydrogen peroxide were added to initiate
the colorimetric reaction; 100 μl of 1 M sulfuric acid was added to stop the reaction.
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The colorimetric reaction was read at 450 nm using a Victor III microplate reader
(Perkin Elmer, Bridgeville, PA).
In vitro human IgG transcytosis. IgG transcytosis was performed as previously
described40–42. BeWo cells, Caco-2 cells or Caco-2 cells transfected with either
pEF6 alone or pEF6-US11 were grown on 0.4 μm Transwell filter inserts (Corning
Costar, Corning, NY) to form a monolayer that exhibited a transepithelial electrical
resistance (TEER) of 600 ohms/cm2 for Caco-2 cells and 400 ohms/cm2 for BeWo
cells, measured using planar electrodes (World Precision Instruments, Sarasota,
FL). Prior to infection, Caco-2 or BeWo cell monolayers were washed twice with
PBS and then were mock-infected or infected with the HCMV clinical strain at an
MOI of 10 for 2 h. After washing, cells were incubated for 48 h at 37 °C in an
atmosphere of 5% CO2. TEER was assessed immediately after adding fresh com-
plete medium to verify that monolayers had remained intact during the infection
procedure. Human IgG was added to the apical surface of the cells at a final
concentration of 0.5 mg/ml (Caco-2 cells) or 0.25 mg/ml (BeWo cells) and
monolayers were incubated for 2 h at either 4 °C or 37 °C. For detecting human
IgG, an aliquot of the basolateral medium was concentrated using a 0.5 ml Amicon
Ultra 10 K centrifugal filter (Millipore, Billerica MA). ELISA was used to quantify
human IgG according to the manufacturer’s instructions (Bethyl Laboratories,
Montgomery, TX). Transported IgG proteins were analyzed by western blot-ECL
or ELISA.
In vitro human IgG protection. Human IgG protection assay was performed in
either HEMC-1 cells (2.5 × 105/ml) or HeLaFcRn+US11, HeLaFcRn, and HeLa cells
(106) that were cultured in complete medium containing 5% FBS with ultra-low
IgG. After cells were infected with HCMV at an MOI of 5 or control for 48 h, they
were incubated with 50 µg/ml of IgG for additional 48 h. The supernatant (50 μl)
was subsequently sampled at 0, 12, 24, 36, and 48 h and stored at 4 °C for ELISA.
To visualize IgG trafficking inside infected HEMC-1 cells (5 × 104), we infected
them with HCMV at an MOI of 5 for 48 h and then incubated them with 250 μg/ml
IgG for 1 h at 37 °C. To visualize IgG trafficking inside US11+ cells, HeLaFcRn+US11
and HeLaFcRn cells were also incubated with 250 µg/ml IgG for 1 h at 37 °C. After
washing, cells were incubated for an additional 1 h in complete medium containing
5% FBS with ultra-low IgG, and then fixed and stained by immunofluorescence for
co-localization of IgG with the early endosomal marker EEA1 or lysosomal marker
LAMP-1. For Pearson’s correlation coefficient measurement, ten microscopic
fields, each of which contained at least ten cells, were measured for correlation
coefficiency rate.
Statistics. The differences between groups were tested by an unpaired two-tailed
Student’s t-test with a significance level of 0.05. Data are expressed as mean ± SEM.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
Sequence data that support this article are available in Genbank under the primary
accession code MK647994. The authors declare that all other relevant data supporting
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